['diabetes mellitus, type 1']
['insulin lispro', 'zp4207 (dasiglucagon)', 'glucagon']

        Inclusion Criteria:

          1. Patients with T1DM for at least 1 year, as defined by the American Diabetes
             Association

          2. Age ≥ 18 years

          3. Prescription medication regimen stable for >1 month (except for medications not
             expected to affect trial safety or outcome, in the judgment of the investigator)

          4. Diabetes managed using an insulin pump for >=6 months

          5. Patients in good health according to age (medical history, physical examination, vital
             signs, 12-lead electrocardiograms [ECGs], laboratory assessments), as judged by the
             Investigator

        Exclusion Criteria:

          1. Previous exposure to ZP4207 or adverse reaction to glucagon

          2. History of liver disease or current abnormal liver function tests (LFTs)

          3. Renal failure

          4. Anemia

          5. History of coronary artery disease or congestive heart failure (class III or IV)

          6. History of transient ischemic attack or stroke

          7. Seizure disorder

          8. Cystic fibrosis, pancreatitis, or any other pancreatic disease besides T1DM

          9. Other endocrine disorders

         10. Use of oral anti-diabetic medications

         11. Electronically powered implants

         12. Hypertension (≥160/100 mm Hg despite treatment)

         13. Inadequate venous (vein) access as determined by trial nurse or physician at time of
             screening
      